QPPV.COM KNOWLEDGE ASSESSMENT

Ixekizumab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Ixekizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should authorised regional product information remain visible during ixekizumab case processing and aggregate review?

Because one global label automatically applies to every jurisdiction Because indication, population, dose, warnings and combination requirements may vary by jurisdiction and change over time Because regional product information determines whether a patient experienced any symptom Because only regional information can be used to assess biological plausibility

Question 2 of 10 Why should signal detection for ixekizumab preserve indication and treatment-line strata?

To ensure that all cases receive different seriousness criteria by indication Because background disease risk, treatment intent, severity and prior therapy can alter event rates and clinical meaning Because stratification eliminates the need for medical review Because only first-line treatment can produce valid safety signals

Question 3 of 10 Which case narrative best supports a clinically meaningful assessment of a suspected ixekizumab-related neutropenia?

“Neutropenia occurred after treatment; causality likely.” A narrative containing baseline and serial counts, symptoms, disease activity, concomitant medicines, treatment changes and clinical consequences A narrative listing only the product name and the patient’s indication A narrative stating that neutropenia is biologically plausible without laboratory values

Question 4 of 10 A periodic benefit-risk review finds serious infections concentrated in a subgroup with substantial baseline immune compromise. What is the most appropriate next interpretation?

The subgroup finding is irrelevant because the product is used across several indications The finding should be examined in relation to baseline risk, treatment context, exposure and benefit in the affected population The finding proves that ixekizumab has no benefit in any population The finding should be removed from the review because it may reflect disease rather than treatment

Question 5 of 10 A fever occurs after an ixekizumab injection. Which interpretation is most scientifically appropriate at the initial review stage?

Fever proves that ixekizumab caused an administration reaction Fever should be assessed against infection, disease activity, administration reaction and other plausible causes Fever can be disregarded because it is not a pathway-specific event Fever should be coded only as treatment failure

Question 6 of 10 A suspected product-quality cluster involving ixekizumab cannot be investigated effectively. Which missing information is most likely to be critical?

The reporter’s preferred communication channel only Presentation, batch, expiry, storage, preparation, administration system and related cases The patient’s disease response without any product details The number of symptoms listed in the narrative

Question 7 of 10 Which statement best describes the role of temporal association in causality assessment?

It is sufficient by itself to establish causality It is unnecessary if the event is medically serious It is usually necessary but should be considered together with mechanism, alternatives and response to withdrawal It is relevant only for immediate injection-site reactions

Question 8 of 10 Which statement best explains why an interruption may not represent a complete dechallenge for ixekizumab?

A biological effect may persist after the last administration, so exposure and effect do not necessarily stop immediately All adverse events continue permanently after a monoclonal antibody is stopped An interruption changes the authorised indication automatically Dechallenge is complete only when a batch number is available

Question 9 of 10 An interruption in ixekizumab treatment is followed by worsening disease several weeks later. Which conclusion is most appropriate?

The worsening is automatically proof of withdrawal toxicity The event should be assessed using schedule, adherence, interruption duration, disease measurements, persistence of biological effect and switching history The event cannot be relevant to pharmacovigilance because treatment was interrupted The worsening should be coded only as an injection-site reaction

Question 10 of 10 Which statement best characterises a pharmacovigilance signal?

A confirmed causal relationship requiring no further investigation A hypothesis or indication of a possible new causal association that requires evaluation Any event listed in product information A single non-serious symptom that must trigger immediate regulatory action

QPPV.com

Ixekizumab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings